Table 1: Laboratory parameters. Centers for Disease Control and Prevention
diagnostic criteria of Multisystem Inflammatory Syndrome in Children (abnormal
findings are bold lettered) [11].
Laboratory parameters |
Reference range |
In the emergency department |
At PICU admission |
Haemoglobin (g/dL) |
12 - 15 |
12.4 |
10.9 |
Platelet count (per μL) |
120000 - 400000 |
270000 |
193000 |
White-cell count (per μL) |
5000 - 14500 |
12000 |
6500 |
Lymphocyte count (per μL) |
2500 - 8500 |
400 |
200 |
Neutrophil count (per μL) |
1800 - 7700 |
10500 |
5700 |
C-reactive protein (mg/L) |
1 - 5 |
147 |
224.5 |
Procalcitonin (ng/mL) |
<0.5 |
- |
1.09 |
Prothrombin activity % |
70 - 150 |
56 |
54 |
International normalized ratio |
0.6 - 1.3 |
1.5 |
1.5 |
Fibrinogen (mg/dL) |
150 - 600 |
945 |
708 |
D-Dimer (ng/mL) |
0.0 - 500 |
- |
7084 |
Interleukin-6 (pg/mL) |
150 - 600 |
- |
734.9 |
Ferritin (ng/mL) |
15 - 150 |
- |
188 |
N-terminal B-type natriuretic peptide (pg/mL) |
Patients with acute dyspnea N-terminal B-type
natriuretic peptide: Heart failure unlikely < 300 Heart failure very likely < 50 years > 450 50-75 years > 900 - > 75 years > 1800 |
- |
1353 |
Troponin I (ng/mL) |
0.000 - 0.120 |
- |
<0.012 |
Centers for Disease Control and Prevention. Case Definition for Multisystem
Inflammatory Syndrome in Children (diagnostic criteria are bold lettered) [8].
An individual aged <21
years presenting fever (>38.0°C for ≥24 hours, or report
of subjective fever lasting ≥24 hours), laboratory evidence of inflammation
(including, but not limited to, one or more of the following: an elevated
C-reactive protein, erythrocyte sedimentation rate, fibrinogen, procalcitonin,
D-Dimer, ferritin, lactic acid dehydrogenase, or Interleukin-6, elevated
neutrophils, reduced lymphocytes and low albumin), and evidence of clinically
severe illness requiring hospitalization, with multisystem (>2) organ
involvement (cardiac, renal, respiratory, hematologic, gastrointestinal,
dermatologic or neurologic); and
No alternative plausible
diagnoses; and
Positive for current or recent SARS-CoV-2
infection by real-time polymerase chain reaction, serology, or antigen
test; or COVID-19 exposure within the 4 weeks prior to the onset of
symptoms.